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The Emerging Role of CTLA-4 Review
as an Immune Attenuator
CTLA-4±Deficient Mice Develop
Lymphoproliferative Disease
Recently, the analysis of CTLA-4±deficient mice has pro-
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vided strong support for an inhibitory role for CTLA-4.Howard Hughes Medical Institute
These mice have a rampant lymphoproliferative disorderDepartment of Medicine
that results in death by 3±4 weeks of age (WaterhouseUniversity of Chicago
et al., 1995; Tivol et al, 1995; Chambers et al., 1997). AnChicago, Illinois 60637
expansion of T cells was observed soon after birth and²Division of Immunology
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ously ex vivo. Lymphoid cells were found infiltrating aHoward Hughes Medical Institute
variety of parenchymal organs, and this infiltration wasUniversity of California
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A variety of mechanisms were offered to account for
this phenotype, including the possibility that deletion
In recent years, a great deal has been learned about of CTLA-4 resulted in the failure of negative selection.
how a T cell±dependent immune response is initiated. According to this model, autoreactive T cells that had
Activation of a naive T cell requires the engagement of escaped negative selection in the thymus would emi-
its antigen-specific T cell receptor (TCR) by a peptide grate and lymphoproliferation would be initiated upon
antigen bound to a major histocompatibility complex their encounter with self-antigens in the periphery. Con-
(MHC) protein. This interaction confers antigen specific- sistent with this model, a diminution of double-positive
ity to a T cell response. Only T cells expressing a TCR thymocytes and a concomitant increase in the absolute
that can bind a given antigen/MHC complex will re- number and frequency of single-positive thymocytes
spond. However, under most circumstances, occupancy were observed in morbid animals. However, T cell devel-
of the TCR is insufficient to initiate a productive T cell opment in the thymus of CTLA-4±deficient mice pro-
response. A successful immune response usually re- ceeds normally even after the lymphoproliferation in the
quires the engagement of additional costimulatory re- periphery is far advanced (Chambers et al., 1997). Al-
ceptors. The best-characterized costimulatory receptor though at present it is not possible to rule out the possi-
expressed on a resting T cell is CD28. Interaction of bility that negative selection has failed, current data do
CD28 with its ligands expressed on the antigen-pre- not support a role for aberrant thymic development in
senting cell (APC) plays a critical role in augmenting the pathogenesis of the lymphoproliferative disease in
CTLA-4±deficient mice. Instead, the developmental dataand sustaining a T cell response initiated through TCR
together with the in vitro functional studies support theengagement.
hypothesis that CTLA-4 plays an essential role in theCD28 shares its ligands, B7-1 and B7-2, with a related
down-regulation of peripheral T cell responses.receptor, CTLA-4 (Figure 1). It has become apparent
Several lymphoproliferative disorders have recentlythat CTLA-4 also plays a very important role in T cell
been linked to abnormalities in the regulation of pro-activation. Initial studies to investigate the role of
grammed cell death (apoptosis) in activated T cells (Ab-CTLA-4 demonstrated that the addition of CTLA-4 anti-
bas, 1996). Consistent with this, the inhibitory effects ofbodies to cultures of activated human T cells resulted in
CTLA-4 on T cell responses have been suggested to beenhanced proliferation and led to the notion that CTLA-4
a consequence of the ability of CTLA-4 ligation to induceprovided a costimulatory signal (Linsley et al., 1992).
T cell apoptosis (Gribben et al., 1995). However, subse-However, subsequent studies using antibodies to mu-
quent studies have failed to document a direct role forrine CTLA-4 demonstrated that while soluble forms of
CTLA-4 in the induction of apoptosis. Instead, it hasCTLA-4 antibodies augmented T cell responses, CTLA-4
been found that CTLA-4 ligation results in inhibition ofantibodies that were either cross-linked or immobilized
interleukin-2 (IL-2) production and a consequent arreston beads had an inhibitory effect on T cell activation
in cell cycle progression from G0/G1, rather than induc-(Walunas et al., 1994; Krummel and Allison, 1995). It was
tion of apoptotic cell death (Krummel and Allison, 1996;also found that both intact and Fab fragments of anti-
Walunas et al., 1996). A common feature of these reportsCTLA-4 enhanced T cell responses in vivo (Kearney et
appears tobe a reversal or inhibition of CD28-dependental., 1995; Krummel et al., 1996). These studies were
aspects of T cell activation. In retrospect, it appearsinterpreted as evidence that CTLA-4 had an inhibitory
that cell death is not a direct effect of CTLA-4 ligationrole in T cell activation. However, these results were
but rather can occur as an indirect consequence of de-controversial and were not generally accepted (Linsley,
priving an IL-2±dependent clone of IL-2.1995).
Temporal Aspects of CTLA-4 Function
Initial studies of CTLA-4 expression suggested that³To whom correspondence should be addressed (e-mail: craig@
knapp.uchicago. edu). CTLA-4 is not detectable on the surface of resting T
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Figure 1. Costimulatory Counterreceptors
CD28, CTLA-4 (CD152), and their shared li-
gands B7-1 (CD80) and B7-2 (CD86) are all
type 1 glycoproteins. Both CD28 and CTLA-4
are expressed primarily as disulfide-linked
homodimers. In contrast, B7-1 and B7-2 are
expressed on the cell surface as monomers.
V, a domain similar to that of an immunoglob-
ulin variable region domain; C, a domain simi-
lar to an immunoglobulin constant region do-
main. Open boxes, transmembrane domains
of each protein.
cells. Instead, CTLA-4 expression was observed 24±48 CD28 and/or deliver inhibitory signals that would pre-
vent T cell activation by interfering with signals emanat-hr after activation (Linsley et al., 1992; Lindsten et al.,
1993; Walunas et al., 1994; Krummel and Allison, 1995). ing from CD28 or the antigen receptor. On the other
hand, when a resting T cell encounters an APC express-This led to the hypothesis that CTLA-4 functions late in
the immune response. That model suggests that the ing high levels of B7, CTLA-4 would be limiting, and
the costimulatory signals generated by CD28 wouldinitial roles for B7-1 and B7-2 are to provide CD28
costimulation to T cells activated by engagement of the dominate, resulting in full T cell activation. One conse-
quence of this activation would be induction of high-antigen receptor. Full activation would result in maximal
expression of CTLA-4, and in subsequent encounters level CTLA-4 expression, reaching maximal levels about
48 hr later. At this point CTLA-4 might again dominateCTLA-4/B7 interactions would dominate. The inhibitory
effects of CTLA-4 would then terminate the immune the response, terminating IL-2 production and produc-
ing a block in cell cycle progression.response, presumably by stopping IL-2 production and
inducing cell cycle arrest. Such an effect could spare It is not yet clear which of two nonexclusive effects
accounts for the abnormalities in T cell proliferation thatsome cells from activation-induced cell death and con-
tribute to development of T cell memory. are observed in CTLA-4±deficient mice. The CTLA-4±
deficient phenotype might result either from failed termi-Recent work, however, suggests that assumptions of
CTLA-4 expression based on maximum appearance at nation of ongoing T cell responses to environmental
antigens or from inappropriate initiation of T cell re-the cell surface may underestimate the time at which
CTLA-4 could be functionally relevant. By Northern blot sponses to self-antigens because of removal of the at-
tenuating effects of CTLA-4. Determining the point atanalysis, CTLA-4 is expressed as early as 1 hr after TCR
activation (Lindsten et al., 1993). In addition, it has been which CTLA-4 functions to regulate an immune response
will have strong implications for our understanding ofshown that CTLA-4 is actually found primarily in intracel-
lular locations and may be rapidly mobilized from those the possible role of CTLA-4 in autoimmune diseases.
Another area that will require further investigation is thelocations to the site of T cell receptor engagement on
the cell surface (discussed in detail below). Small num- relationship between activation-induced cell death and
CTLA-4 mediated mechanisms in the termination of Tbers of these intracellular molecules, if mobilized to the
right location, might have profound effects on T cell cell responses.
activation. Indeed, engagement of CTLA-4 can prevent
accumulation of IL-2 as early as 16 hr after activation. In Vivo Effects of CTLA-4 Antibodies
The expression of activation markers CD69 and CD44 Manipulation of CTLA-4 in vivo has been demonstrated
can be observed to be inhibited by CTLA-4 at as early to have important effects on T cell responses. It has
as 12 hr of activation (Krummel and Allison, 1996). Under been shown that administration of CTLA-4 antibodies
suboptimal activation conditions, CTLA-4 might serve exacerbates the severity of experimental autoimmune
to attenuate weak signals mediated by the antigen re- encephalomyelitis in murine models (Karandikar et al.,
ceptor and CD28. Early expression of CTLA-4 could 1996; Perrin et al., 1996; Hurwitz et al., 1997). Similarly,
prevent full progression to activation and in that way CTLA-4 antibodies can greatly enhance anti-tumor T
might contribute to peripheral tolerance (Chambers et cell responses and in some cases can result both in
al., 1996). complete rejection of the tumor and in immunity to re-
A model suggesting a role for CTLA-4 in both early challenge with tumor (Leach et al., 1996; Kwon et al.,
and late stages of the immune response is shown in 1997). These results, together with the observations that
Figure 2. As in the conventional two-signal model, an anti-CTLA-4 treatment can promote the expansion of
encounter by a T cell with antigen presented by an APC antigen- and superantigen-specific T cells (Kearney et
that did not express B7 would not result in activation, al., 1995; Krummel et al., 1996), suggest that CTLA-4
because of the lack of CD28-mediated costimulation. blockade may have clinical utility in situations where
An encounter with antigen on an APC expressing low enhancement of immune responses is desired. What
levels of B7 also would fail to result in activation, be- remains to be demonstrated is whether strategies can
cause of inhibition by CTLA-4. Despite its low abun- be developed to exploit the inhibitory effects of CTLA-4
dance on naive or recently stimulated cells, CTLA-4 has engagement to specifically turn off or prevent T cell
a much higher affinity than CD28 for B7, and under responses in transplantation, autoimmunity, or allergy.
This possibility is exciting, given a recent report thatconditions of limited B7 availability might outcompete
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Figure 2. Proposed Role for CTLA-4/B7 In-
teractions in Regulating Both Early and Late
Stages of T Cell Responses
According to this model, under suboptimal
conditions of costimulation, CTLA-4 might
compete for B7 or generate inhibitory signals
that would prevent full activation. However,
under optimal conditions for costimulation,
CTLA-4 would become limitingand T cellacti-
vation would proceed. One consequence of
this activation would be induction of CTLA-4
to high levels of expression, which could then
dominate and terminate T cell responses.
CTLA-4 engagement may be required for the induction sequenced (Waterhouse et al., 1996), but in contrast, in
these species the extracellular domain retains approxi-of anergy in vivo (Perez et al., 1997).
mately 70% amino acid identity. The apparently high
selective pressure for maintenance of the CTLA-4 cyto-CTLA-4 as Competitive Antagonist of CD28
plasmic domain suggests that this domain plays an im-How the CTLA-4 receptor mediates its biological effects
portant role in regulating the function of CTLA-4.remains controversial. In the simplest terms, CTLA-4
One biological role for the cytoplasmic domain ofmay inhibit T cell activation by competing with CD28
CTLA-4 has been identified. The cytoplasmic tail canfor ligand binding. Although estimates of the affinity of
function to prevent the cell surface accumulation ofCTLA-4 and CD28 for B7-1 and B7-2 have varied widely,
translated CTLA-4 in activated T cells. This intracellularCTLA-4 has been found to have at least a 10-fold higher
accumulation was initially believedto be due to retentionaffinity for B7-1 and B7-2 than CD28 (Linsley et al. 1991;
of CTLA-4 in the trans-Golgi compartment (Leung et al.,van der Merwe et al., 1997). Therefore if the expression
1995). However, it was recently demonstrated that cellof CTLA-4 is greater than that of available ligand, CTLA-4
surface expression of CTLA-4 is limited by its rapidcould prevent CD28 activation. Consistent with the hy-
clearance from the surface of activated T cells throughpothesis that CTLA-4 functions primarily to limit ongoing
clathrin-mediated endocytosis (Chuang et al., 1997). AnCD28 signal transduction, an early study was unable to
11±amino acid sequence within the cytoplasmic tail of
identify CTLA-4±dependent effects on the proliferation
CTLA-4 plays a critical role in regulating intracellular
of CD28-deficient T cells (Green et al., 1994). In addition,
accumulation. A 6±amino acid sequence within this do-
the phenotype of mice lacking both B7-1 and B7-2 is
main (amino acids 199±204) can bind specifically to the
similar to that of CD28-deficient animals (Borriello et al., medium chain subunit (AP50) of the clathrin-associated
1997). Both types of animals exhibit defects in immune protein complex AP-2 (Chuang et al., 1997; Shiratori et
activation and germinal center formation. The pheno- al., 1997; Zhang and Allison, 1997). The AP-2 complex
type of B7-12/2 B7-22/2 mice suggests that the inability plays an important role in targeting cell surface glyco-
to engage the CTLA-4 receptor does not result in a proteins for endocytosis. Mutations of CTLA-4 that abro-
lymphoproliferative disorder in the absence of CD28 gate the interaction with AP50 result in accumulation of
signal transduction. Since CD28 has been shown to up- CTLA-4 at the cell surface. The intracellular storage pool
regulate CTLA-4 expression on activated T cells (Linds- of CTLA-4 appears to colocalize with the storage com-
ten et al., 1993), the ability of CTLA-4 to sequester B7-1 partment for the transferrin receptor (Alegre et al., 1996;
and B7-2 would provide a feedback mechanism to limit Linsley et al., 1996). Under some conditions this storage
CD28 costimulation. pool can rapidly remobilize to the cell surface. Thus,
One problem with this model is that the amount of activated T cells contain much higher levels of CTLA-4
cell surface CTLA-4 observed on activated cells appears than has previously been estimated by cell surface stud-
to be only 3%±5% of the amount of cell surface CD28 ies. Redistribution of this pool to the cell membrane
(Linsley et al., 1992). At these levels CTLA-4 is unlikely would limit ligand-mediated CD28 activation.
to displace CD28 effectively from their shared ligands The endosomal pool of CTLA-4 appears to recirculate
despite a higher ligand affinity. This suggests that when constantly. Therefore any alteration that inhibits CTLA-4
CD28 and CTLA-4 are simultaneously expressed on acti- endocytosis will lead to CTLA-4 accumulation at the cell
vated T cells, both are likely to engage ligand. The ob- surface. Both B7-1 and B7-2 are cell-bound ligands.
served ability of CTLA-4 to inhibit CD28-dependent Therefore, ligand binding could sterically inhibit CTLA-4
activation has therefore led a number of investigators endocytosis. Alternatively, modification of the AP50
to propose that CTLA-4 initiates a signal transduction binding site in the CTLA-4 cytoplasmic domain, perhaps
cascade that can inhibit T cell activation. The cyto- by phosphorylation of tyrosine 201, might interrupt the
plasmic domain of CTLA-4 is 100% conserved in each targeting of CTLA-4 for intracellular storage. CTLA-4
appears to have its most potent inhibitory effects onof the mammalian species in which CTLA-4 has been
Immunity
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Figure 3. Potential Signaling Domains of the
CTLA-4 Cytoplasmic Tail and Its Role in Reg-
ulating CTLA-4 Intracellular Trafficking and
Signal Transduction
(A) The sequence of the CTLA-4 cytoplasmic
tail. Established AP-2 and SH2 binding sites
as well as a putative binding SH3 binding site
are indicated.
(B) Schematic diagram of the trafficking of
cell surface CTLA-4 and its potential role in
regulating T cell/APC interactions.
cell proliferation when it is colocalized to the site of TCR had phosphatase activity against the Ras regulatory
protein p52SHC. Based on these observations, CTLA-4engagement (Krummel and Allison, 1996; Walunas et
might initiate a signal transduction cascade that results,al., 1996). The in vivo effects of CTLA-4 could be the
either directly or indirectly, in the dephosphorylationresult of ligand-dependent colocalization with the TCR.
of the TCR-associated kinases or their substrates. InDuring in vivo antigen presentation, CTLA-4 ligands and
addition to SHP-2, phosphatidylinositol 3-kinase (PI3K)peptide/MHC complexes are likely to be expressed on
subunit p85 has also been shown to be capable of bind-the same cell, and therefore the B7-1 and B7-2 ex-
ing to the phosphorylated YVKM motif (Schneider etpressed by the APC are likely to result in recruitment of
al., 1995). Whether such results reflect a potential forCTLA-4 to the site of TCR engagement. Once colocal-
differential signal transduction through CTLA-4 or merelyized to the TCR, the CTLA-4/B7 complex might have an
establish this sequence as an authentic SH2 bindinginhibitory effect simply by preventing TCR mobility and/
site remains to be determined. PI3K binding of CTLA-4or coreceptor association. Under these conditions,
might result in T cell inhibition if CTLA-4 sequestersCTLA-4 might block the ability of peptide/MHC and TCR
PI3K, preventing it from participating in TCR and/ormolecules to diffuse rapidly into and out of the contact
CD28 signal transduction. Alternatively, there may bezone between T cells and the APC. This could result in
secondary conditions that lead CTLA-4 to bind and acti-the failure of the peptide/MHC complexes to stimulate
vate PI3K instead of SHP-2 (Hutchcroft and Bierer,sufficient TCRs to maintain immune activation.
1996). Such a circumstance could account for the re-
ported ability of CTLA-4 to act as a costimulatory recep-CTLA-4 Signal Transduction
tor under some in vitro conditions (Wu et al., 1997).
CTLA-4 may also regulate T cell activation through intra-
How CTLA-4 signal transduction might be initiated by
cellular signal transduction. The primary amino acid se- ligand binding has not been established. Both B7-1 and
quence of the CTLA-4 cytoplasmic domain suggests B7-2 are expressed as monomers on the surface of APC.
that it may contain two potential binding sites for Src The CTLA-4 receptor is expressed predominantly as a
homology domain 2 (SH2) as well as a potential binding covalent homodimer (Figure 1), an unusual structure for
motif for an SH3 domain (Waterhouseet al., 1996) (Figure a signaling receptor. To establish a signaling cascade,
3A). In the T cells of CTLA-4±deficient animals, the T CTLA-4 may need to be brought into proximity with
cell receptor-associated kinases Fyn, Lck, and ZAP-70 additional receptor component(s). Alternatively, CTLA-4
were found to be constitutively activated, and there was may function as a regulatory component of a larger
a profound increase in the tyrosine phosphorylation of receptor complex.For CTLA-4 to participate in the signal
intracellular proteins. Based on these observations, the transduction events proposed above, its proximal SH2
potential of CTLA-4 to associate with molecules that binding site must be activated by phosphorylation. Such
might regulate intracellular phosphorylation has been phosphorylation could occur if ligand binding brought
investigated (MarengeÁ re et al., 1996). CTLA-4 was found CTLA-4 in proximity to TCR-activated tyrosine kinases
to associate with SH2-containing tyrosine phosphatase-2 at the site of APC/T cell interaction.
(SHP-2), and this interaction appeared to be mediated A model for the role of CTLA-4 in T cell activation is
beginning to emerge (Figure 3B). The ability of CTLA-4by the SH2 domain of SHP-2. CTLA-4±associated SHP-2
Review
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to inhibit an activated T cell results from the recruitment pathogenesis of autoimmune disease, as demonstrated
both by gene knockout studies in mice and by geneticof CTLA-4 to the site of APC/T cell interaction. This
recruitment occurs as a result of ligand interaction.Once linkage analysis in human autoimmune disorders.
colocalized to the site of TCR engagement, CTLA-4 can
be phosphorylated by TCR-associated tyrosine kinases,
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